Literature DB >> 15192163

Evolving immunotherapeutic strategies in bladder and renal cancer.

T R L Griffiths1, J K Mellon.   

Abstract

For patients with urological cancers, immunotherapy is currently a treatment option for metastatic renal cell carcinoma, and those with "high risk" superficial bladder cancers. In this review, our current understanding of tumour immune escape is discussed. The principles and role of current immunotherapies for these tumours are described, and new areas of immunotherapeutic promise are highlighted.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15192163      PMCID： PMC1743027          DOI： 10.1136/pgmj.2003.013508

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  56 in total

1.  Intravesical adjuvant treatment in superficial bladder cancer. A review of the question after 15 years of experience with the EORTC GU group.

Authors:  C Bouffioux
Journal:  Scand J Urol Nephrol Suppl       Date:  1991

2.  Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity.

Authors:  Y Luo; X Chen; R Han; M A O'Donnell
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

3.  T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer.

Authors:  F Saint; J J Patard; P Maille; P Soyeux; A Hoznek; L Salomon; A De La Taille; C C Abbou; D K Chopin
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

4.  Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed.

Authors:  M A O'Donnell; J Krohn; W C DeWolf
Journal:  J Urol       Date:  2001-10       Impact factor: 7.450

5.  Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder.

Authors:  A Morales; J L Chin; E W Ramsey
Journal:  J Urol       Date:  2001-11       Impact factor: 7.450

6.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Authors:  G H Mickisch; A Garin; H van Poppel; L de Prijck; R Sylvester
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  Expression of class I histocompatibility antigens in transitional cell carcinoma of the urinary bladder in relation to survival.

Authors:  I Levin; T Klein; J Goldstein; O Kuperman; J Kanetti; B Klein
Journal:  Cancer       Date:  1991-12-15       Impact factor: 6.860

8.  Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.

Authors:  S A Rosenberg; M T Lotze; J C Yang; S L Topalian; A E Chang; D J Schwartzentruber; P Aebersold; S Leitman; W M Linehan; C A Seipp
Journal:  J Natl Cancer Inst       Date:  1993-04-21       Impact factor: 13.506

9.  A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder.

Authors:  P D Vegt; J A Witjes; W P Witjes; W H Doesburg; F M Debruyne; A P van der Meijden
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

10.  Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer.

Authors:  J Atzpodien; H Kirchner; E L Hänninen; M Deckert; M Fenner; H Poliwoda
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162
View more
  1 in total

1.  Shared occupational risks for transitional cell cancer of the bladder and renal pelvis among men and women in Sweden.

Authors:  Robin Taylor Wilson; Mark Donahue; Gloria Gridley; Johanna Adami; Laure El Ghormli; Mustafa Dosemeci
Journal:  Am J Ind Med       Date:  2008-02       Impact factor: 2.214
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.